DelSiTech Secures Further Funding for In-House Program

DelSiTech Ltd (info a, Jul 5th 2017

Finnish drug delivery technology company DelSiTech Ltd announced today that it has been awarded additional funding by Tekes, the Finnish Funding Agency for Innovation.  The funds will support the further advancement of DelSiTech’s in-house program, a long acting supergeneric/505(b)(2) hepatitis B product, 1308.  1308, a 3 month subcutaneous depot of entecavir, has completed all of the preclinical studies and will enter the clinic in H2 2017 in a healthy volunteer study in Finland.

"We are very pleased with the long-lasting partnership with Tekes which is the leading public funding organisation for high-tech  companies in Finland", said Lasse Leino, CEO of DelSiTech Ltd. "The new funding highlights the general acceptance of DelSiTech's technology by various stakeholders, and it continues the very positive trend in the company's business at the moment."